Five-year nationwide follow-up study of active surveillance for prostate cancer.

[1]  J. Richie,et al.  Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Stattin,et al.  Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. , 2013, The Journal of urology.

[3]  P. Stattin,et al.  Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. , 2013, International journal of epidemiology.

[4]  N. Nicolai,et al.  Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. , 2013, European urology.

[5]  A. Costello,et al.  Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011 , 2013, The Medical journal of Australia.

[6]  M. Cooperberg,et al.  Active surveillance for prostate cancer: a systematic review of the literature. , 2012, European urology.

[7]  D. Latini,et al.  Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance , 2012, BJU international.

[8]  P. Corso,et al.  National Institutes of Health State-of-the-Science Conference: Role of Active Surveillance in the Management of Men With Localized Prostate Cancer , 2012, Annals of Internal Medicine.

[9]  P. Corso,et al.  National Institutes of Health State-of-the-Science Conference , 2012 .

[10]  T. Gomes,et al.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. , 2012 .

[11]  Alan W Partin,et al.  Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience , 2011 .

[12]  L. Holmberg,et al.  Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. , 2011, The Journal of urology.

[13]  J. Thrasher,et al.  Active surveillance for prostate cancer in a veteran population. , 2010, The Canadian journal of urology.

[14]  C. Parker,et al.  Initial management of low‐risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry , 2010, BJU international.

[15]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Carroll,et al.  The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. , 2007, The Journal of urology.

[17]  W. Catalona,et al.  Primary treatment choices for men with clinically localized prostate carcinoma detected by screening , 2000, Cancer.

[18]  J. Hugosson,et al.  Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. , 2013, European urology.

[19]  J. Lau,et al.  Active surveillance in men with localized prostate cancer: a systematic review. , 2012, Annals of internal medicine.

[20]  J Concato,et al.  Treatment decisions for localized prostate cancer , 2000, Journal of General Internal Medicine.